BrainPort Vision Device
Device2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
NCT Number: NCT01488786
The purpose of this study is to assess the safety of the BrainPort vision device and to demonstrate improved object recognition and word identification and ambulation with use of the BrainPort vision device in subjects who are medically documented as blind, with acuity of 20/ 5000 or worse.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Not applicable
Canadian National Institute for the Blind, Toronto, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
Time frame: 1 year
The primary safety objective is to demonstrate that the rate of clinically significant device-related adverse events is less than 10%. This will require an observed event-free rate of approximately 97%.
Time frame: 1 year
The primary efficacy objective is to demonstrate that at least 50% of subjects achieve a success rate in object recognition exceeding that expected by chance alone.
Time frame: 1 year
A secondary efficacy objective is to demonstrate that at least 50% of subjects correctly identify at least 50% of a series of three- to five-letter words.
Time frame: 1 year
Another secondary efficacy objective is to demonstrate at least 35% of subjects demonstrate sign recognition in a mobility task.
Wicab
Industry
A Study to Evaluate the Safety and Efficacy of the BrainPort® Vision Device in Subjects Who Are Blind
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06318000
Blindness, Eye Diseases
Warsaw, Poland
View Trial DetailsNCT02643238
Blindness, Eye Diseases
Akron, Ohio, United States
View Trial DetailsNCT05608811
Blindness, Blindness Congenital
Ankara, Turkey (Türkiye)
View Trial DetailsNCT04936100
Blindness, Eye Diseases
Tehran, Iran
View Trial Details